Home
  • E-mailRuth.Brenk@uib.no
  • Phone+47 55 58 60 70
  • Visitor Address
    Jonas Lies vei 91
    Room 
    5A125B
  • Postal Address
    Postboks 7804
    5020 Bergen

Our overall research goal is to improve methods used for structure-based drug design and to apply these methods to design inhibitors for enzymes with biological relevance. A key point in our research is the interplay of theoretical and experimental methods.

To read more about what we do, check out our homepage .

 

For a full list of publications click here.

Academic article
  • Show author(s) 2021. DrugPred_RNA—A Tool for Structure-Based Druggability Predictions for RNA Binding Sites. Journal of Chemical Information and Modeling.
  • Show author(s) 2020. Targeting the Class A Carbapenemase GES-5 via Virtual Screening. Biomolecules.
  • Show author(s) 2019. Identification of a potential allosteric site of Golgi α-mannosidase II using computer-aided drug design. PLOS ONE. 1-19.
  • Show author(s) 2019. How To Design Selective Ligands for Highly Conserved Binding Sites: A Case Study Using N-Myristoyltransferases as a Model System. Journal of Medicinal Chemistry.
  • Show author(s) 2018. In silico identification and experimental validation of hits active against KPC-2 β-lactamase. PLOS ONE.
  • Show author(s) 2015. To hit or not to hit, that is the question -genome-wide structure-based druggability predictions for pseudomonas aeruginosa proteins. PLOS ONE.
Academic lecture
  • Show author(s) 2021. Structure-based ligand design for protein and RNA targets for new antibiotics.
  • Show author(s) 2021. Structure-based ligand design for protein and RNA targets for new antibiotics.
  • Show author(s) 2021. Structure-based ligand design for protein and RNA targets for new antibiotics.
Masters thesis
  • Show author(s) 2021. The Search for Antibiotic Leads: Targeting Pantothenate Kinase in Pseudomonas aeruginosa.
  • Show author(s) 2020. Structure-based design of pantothenate kinase inhibitors as lead structures for new antibiotics.
Academic literature review
  • Show author(s) 2021. Riboswitches as Drug Targets for Antibiotics. Antibiotics. 1-22.
  • Show author(s) 2021. Fragment-Based Drug Discovery for RNA Targets. ChemMedChem.
  • Show author(s) 2017. Ligand design for riboswitches, an emerging target class for novel antibiotics. Future Medicinal Chemistry. 1649-1662.
Article in business/trade/industry journal
  • Show author(s) 2021. An Experimental Toolbox for Structure-Based Hit Discovery for P. aeruginosa FabF, a Promising Target for Antibiotics . ChemMedChem.
Chapter
  • Show author(s) 2017. Structure-Based Discovery of Small Molecules Binding to RNA. . In:
    • Show author(s) 2017. RNA Therapeutics. Springer.

More information in national current research information system (CRIStin)

Research groups

Twitter